Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
addressing, adipocytic, ambiguity, Andre, Anita, appointed, approach, argument, Asia, attorney, Av, Biarritz, biennially, Blackrock, bond, branch, calendar, Casino, CentRx, choice, complaint, couple, covalent, defense, deficiency, del, diagnostic, disgorgement, District, docetaxel, Document, doubt, DreamTeam, DreamTeamGroup, duration, East, economist, enrichment, equitable, Este, etoposide, faith, Fishman, Francia, freelance, Genentech, German, GP, Halaven, heard, HR, Hycamtin, infrastructure, injunctive, Instance, instructor, instrumental, interactive, investor, ipilumimab, irinotecan, Italy, Jamaica, Janssen, knowable, Latin, lawsuit, leiomyosarcoma, length, lesion, Linkbase, liposarcoma, LP, matter, medstat, Michigan, mismanagement, MissionIR, modest, monetary, motion, multicenter, Nataliya, Neoplasia, nivolumab, nonmonetary, NY, Oct, online, OS, Pacific, Pankratz, passed, passing, PCT, PhD, PJWx, plaintiff, positon, prejudice, promptly, Punta, purported, QVT, Rajasekaran, relatied, remeasured, remeasurement, restitution, risky, Schwartz, science, SCLC, shelf, significiant, Silverberg, Spain, specialty, Subtopic, surrendered, taught, Taxonomy, Taylor, Thomson, Threshold, timeline, topotecan, Tower, traceable, translational, unaffiliated, unified, unjust, unspecified, Uruguay, veliparib, vigorously, vinorelbine, voice, voluntarily, VWAP, Warnecke, waste, Wellesley, writer, XBRL, Yervoy
Removed:
accurate, Advisor, Alexion, ALSCRT, APL, bafetinib, Basel, bid, bioavailable, Boehringer, Celsion, Centerpulse, CMS, concept, consolidation, consultation, controller, Cooperation, Corange, delineation, DePuy, differentiation, discounted, EMCH, exist, facing, Fernando, finite, Foundation, founded, Fyn, Genome, Gleevec, grown, guiding, hematological, inhibitor, involvement, IRA, Japan, Japanese, kinase, leader, leasing, lectured, leukemia, lived, LPA, lymphocytic, Lyn, Mannheim, marketable, Nippon, nonvested, Olive, orally, originated, pathway, positioning, potent, presiding, promyelocytic, proportional, PTC, rationally, recipient, rendering, resistance, resistant, retinoic, retinoid, Rollover, RXi, Shinyaku, signaling, Src, synthetic, tentative, terminable, Threshhold, TMRC, Treaty, tyrosine, undertook, utility, Valley, valuable, weak, weight, Zimmer
Filing tables
Filing exhibits
- 10-K Annual report
- 10.23 Daniel Levitt Employment Agreement
- 10.34 Steven Kriegsman Employment Agreement
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of CEO
- 31.2 Certification of CFO
- 32.1 Second Certification of CEO
- 32.2 Second Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
LADX similar filings
Filing view
External links
Exhibit 32.1
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CytRx Corporation (the “Company”) hereby certifies that:
(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 10, 2015 | By: | /s/ STEVEN A. KRIEGSMAN | |
Steven A. Kriegsman | |||
Chief Executive Officer | |||
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (Section 906), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to CytRx Corporation and will be retained by CytRx Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-K and shall not be considered filed as part of the Form 10-K.